HER2 amplification/overexpression has been seen in many cancer types; among GI cancers, the rates of such alterations are highest in gastroesophageal cancers, but HER2 alterations are also seen in pancreatic, colorectal, and biliary tract cancers (particularly GBAs). Here, ERBB2 is linked to biliary tract cancer.